CENTOGENE Announces Leadership Transition - Seite 2
Under Prof. Rolfs’ leadership, CENTOGENE has evolved from its inception in 2006 into what is now the world’s leading partner and knowledge resource for diagnosis and research around rare diseases. CENTOGENE is a global company that employs over 500 experts and contributors from over 50 nations and helps transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies.
“It has been a great honor to lead this groundbreaking Company for 16 years, and I am proud of all we as a team have accomplished for patients with rare genetic diseases around the world,” commented Prof. Arndt Rolfs. “CENTOGENE has a clear mission and a committed and excellent team that will help drive a very exciting future for the Company. Our recently updated guidance speaks to the team’s so valuable contributions and the strength and agility of the business, which continues to recover nicely from the impact of COVID-19. I have decided that the Company is now in a great position to enter into a new phase of its journey and that this is a good time to allow new leadership to shape its future. I intend to participate in its future as a shareholder and look forward to working closely with the management team to ensure a smooth transition for the benefit of our patients, employees, partners, shareholders, and other stakeholders, as CENTOGENE continues to play a critical role in how we diagnose and treat rare diseases.”
Additional Background on Andrin Oswald, MD
Dr. Oswald was most recently the Delegate for COVID-19 Vaccines and Immunotherapies for the Federal Government of Switzerland, helping develop response and procurement strategies while advising the Swiss government on key decisions.
Prior to that, he was Director of Life Science Industry Engagement and Partnerships at the Bill & Melinda Gates Foundation, a role he held for four years in which he led the Foundation’s engagement with the industry and supported teams in developing and advancing its Global Health and Development priorities in R&D and delivery technologies. Prior to his role at the Bill & Melinda Gates Foundation, he oversaw business integration at GlaxoSmithKline, working directly with the CEO to advise on business and integration strategy. Before joining GlaxoSmithKline, Dr. Oswald spent more than 10 years in a variety of leadership roles at Novartis, including serving as Assistant to the Chairman and CEO of Novartis International AG; Country President for Novartis South Korea; Head of Global Development Franchises and a member of the Executive Committee for Novartis Pharma; and ultimately, CEO/Division Head of Novartis Vaccines & Diagnostics and a member of the Novartis Executive Committee, based in Boston. Dr. Oswald began his career in 1999 with McKinsey & Company, where he worked in various roles managing relationships and supporting projects with leading pharmaceutical and diagnostics companies in Europe and the U.S.